GLYXAMBI 25/5MG

About

GLYXAMBI 25/5MG is a combination medication containing empagliflozin (25mg) and linagliptin (5mg), used for the treatment of type 2 diabetes mellitus. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and thus lowering blood sugar levels. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the levels of incretin hormones, which stimulate insulin release and decrease glucagon secretion in a glucose-dependent manner, further helping to control blood glucose.

This dual-action medication provides comprehensive glycemic control by targeting different pathways involved in glucose regulation. It is typically used as an adjunct to diet and exercise in adults with type 2 diabetes to improve glycemic control. Beyond its glucose-lowering effects, empagliflozin has also demonstrated cardiovascular and renal benefits in certain patient populations, making GLYXAMBI a valuable option for managing complex type 2 diabetes.

Uses

• Treatment of type 2 diabetes mellitus in adults.
• To improve glycemic control as an adjunct to diet and exercise.
• To reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
• To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes.

Directions For Use

Take one tablet orally once daily in the morning, with or without food, as prescribed by your doctor. Swallow the tablet whole.

Benefits

• Effectively lowers blood glucose levels.
• Provides dual mechanism of action for comprehensive control.
• May reduce the risk of cardiovascular death.
• May reduce the risk of hospitalization for heart failure.
• Contributes to modest weight loss.
• Generally well-tolerated.

Side Effects

• Urinary tract infections (UTIs)
• Genital yeast infections
• Increased urination
• Nausea
• Diarrhea
• Headache
• Joint pain
• Hypoglycemia (when used with insulin or sulfonylureas)
• Nasopharyngitis
• Back pain
• Fatigue
• Pancreatitis (rare)

Safety Measures

• Alcohol - Limit alcohol intake as it can affect blood sugar levels and increase the risk of hypoglycemia.
• Pregnancy - Not recommended during pregnancy; consult a doctor as it may harm the fetus.
• Breastfeeding - Not recommended during breastfeeding; consult a doctor as it may pass into breast milk.
• Liver - Use with caution in patients with hepatic impairment; no dose adjustment typically needed for linagliptin.
• Kidney - Not recommended for severe renal impairment or end-stage renal disease; dose adjustment may be needed.
• Lung - No specific contraindications related to lung conditions are typically noted.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.